{"id":390754,"date":"2017-12-26T00:00:00","date_gmt":"2017-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2017-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-29T23:23:11","modified_gmt":"2026-04-29T23:23:11","slug":"dlsfon0005-2017-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2017-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Multiple Myeloma | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><br \/>\nCelgene\u2019s Revlimid and Janssen\/Takeda Pharmaceutical\u2019s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie\/Roche\/Genentech\u2019s Venclexta\/Venclyxto, and Karyopharm Therapeutics\u2019 selinexor are pursuing initial approvals for the treatment of multiple myeloma. This highlights the fact that untapped clinical and commercial potential remains in multiple myeloma for therapies with improved efficacy, novel mechanisms of actions, and for agents positioned in patient segments that are currently underserved.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the myeloma market?<\/li>\n<li>How has the approval of Janssen\u2019s Darzelex and Bristol-Myers Squibb\/AbbVie\u2019s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?<\/li>\n<li>What are though leaders\u2019 opinions on agents in Phase III development for multiple myeloma, such as Merck &#038; Co\u2019s Keytruda, Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s Opdivo, Sanofi\/ImmunoGen\u2019s isatuximab, and PharmaMar\/Chugai Pharmaceutical\u2019s Aplidin? What impact will these agents have on the multiple myeloma market?<\/li>\n<li>What are the market drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><br \/>\nDisease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390754","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-myeloma","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390754\/revisions"}],"predecessor-version":[{"id":576758,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390754\/revisions\/576758"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}